Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Elastic NV (ESTC) Price & Performance

Charles River Laboratories Intl. IncTrade
Elastic NVTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Elastic NV — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Elastic NV trades at $62.59 (market cap $6.48B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Elastic NV nearer its low. Which is the better fit depends on your goals.

CRLESTC
Market Cap
$11.14B$6.48B
Sector
HealthTechnology
52-Week High
$233.60$94.47
52-Week Low
$145.57$43.30
Enterprise Value
$14.00B$5.70B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Elastic NV

Elastic N.V. (ESTC) trades at $62.43, up 3.64% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and projected revenue growth from $1.48B to $1.7B. Technical indicators signal bullish momentum, though RSI suggests potential overbought conditions near-term.

ESTC presents a compelling growth opportunity with 67.65% analyst buy ratings and a $72.80 consensus target, offering 16.6% upside. Key risks include ongoing legal investigations and the transition to profitability after 2025's net loss. The company's leadership in SIEM and AI capabilities supports long-term growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Elastic NV

Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.

Read more on ESTC